Clinical Trials Browser

Phase 1/2 × Filgrastim × 30 days × Clear all

NCT04959175 2026-04-09

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Phase 1/2 Recruiting

Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

NCT05436418 2026-03-20

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Hematologic Neoplasms